Literature DB >> 9529050

Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

B Haneberg1, R Dalseg, E Wedege, E A Høiby, I L Haugen, F Oftung, S R Andersen, L M Naess, A Aase, T E Michaelsen, J Holst.   

Abstract

A nasal vaccine, consisting of outer membrane vesicles (OMVs) from group B Neisseria meningitidis, was given to 12 volunteers in the form of nose drops or nasal spray four times at weekly intervals, with a fifth dose 5 months later. Each nasal dose consisted of 250 microg of protein, equivalent to 10 times the intramuscular dose that was administered twice with a 6-week interval to 11 other volunteers. All individuals given the nasal vaccine developed immunoglobulin A (IgA) antibody responses to OMVs in nasal secretions, and eight developed salivary IgA antibodies which persisted for at least 5 months. Intramuscular immunizations did not lead to antibody responses in the secretions. Modest increases in serum IgG antibodies were obtained in 5 volunteers who had been immunized intranasally, while 10 individuals responded strongly to the intramuscular vaccine. Both the serum and secretory antibody responses reached a maximum after two to three doses of the nasal vaccine, with no significant booster effect of the fifth dose. The pattern of serum antibody specificities against the different OMV components after intranasal immunizations was largely similar to that obtained with the intramuscular vaccine. Five and eight vaccinees in the nasal group developed persistent increases in serum bactericidal titers to the homologous meningococcal vaccine strain expressing low and high levels, respectively, of the outer membrane protein Opc. Our results indicate that meningococcal OMVs possess the structures necessary to initiate systemic as well as local mucosal immune responses when presented as a nasal vaccine. Although the serum antibody levels were less conspicuous than those after intramuscular vaccinations, the demonstration of substantial bactericidal activity indicates that a nonproliferating nasal vaccine might induce antibodies of high functional quality.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9529050      PMCID: PMC108057     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Effects of sample processing on the measurement of specific intestinal IgA immune responses.

Authors:  B D Forrest
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

2.  Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA.

Authors:  E Wedege; E A Høiby; E Rosenqvist; L O Frøholm
Journal:  J Med Microbiol       Date:  1990-03       Impact factor: 2.472

3.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.

Authors:  G Bjune; E A Høiby; J K Grønnesby; O Arnesen; J H Fredriksen; A Halstensen; E Holten; A K Lindbak; H Nøkleby; E Rosenqvist
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

4.  Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey.

Authors:  E A Høiby; E Rosenqvist; L O Frøholm; G Bjune; B Feiring; H Nøkleby; E Rønnild
Journal:  NIPH Ann       Date:  1991-12

5.  Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial.

Authors:  E Wedege; G Bjune; L O Frøholm; E A Høiby; E Rosenqvist
Journal:  NIPH Ann       Date:  1991-12

6.  Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland.

Authors:  B A Perkins; K Jonsdottir; H Briem; E Griffiths; B D Plikaytis; E A Hoiby; E Rosenqvist; J Holst; H Nokleby; F Sotolongo; G Sierra; H C Campa; G M Carlone; D Williams; J Dykes; D Kapczynski; E Tikhomirov; J D Wenger; C V Broome
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

Review 7.  Humoral immune response patterns of human mucosae: induction and relation to bacterial respiratory tract infections.

Authors:  P Brandtzaeg
Journal:  J Infect Dis       Date:  1992-06       Impact factor: 5.226

8.  Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting.

Authors:  E Wedege; L O Frøholm
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

9.  Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule.

Authors:  G A Jarvis; J M Griffiss
Journal:  J Immunol       Date:  1991-09-15       Impact factor: 5.422

10.  Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease.

Authors:  J H Fredriksen; E Rosenqvist; E Wedege; K Bryn; G Bjune; L O Frøholm; A K Lindbak; B Møgster; E Namork; U Rye
Journal:  NIPH Ann       Date:  1991-12
View more
  40 in total

1.  Immunogenicity and safety testing of a group B intranasal meningococcal native outer membrane vesicle vaccine.

Authors:  Rohit K Katial; Brenda L Brandt; Ellen E Moran; Stephen Marks; Victor Agnello; Wendell D Zollinger
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  Human opsonins induced during meningococcal disease recognize outer membrane proteins PorA and PorB.

Authors:  A K Lehmann; A Halstensen; I S Aaberge; J Holst; T E Michaelsen; S Sornes; L M Wetzler; H Guttormsen
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a.

Authors:  Kingston H G Mills; Catherine Cosgrove; Edel A McNeela; Amy Sexton; Rafaela Giemza; Inderjit Jabbal-Gill; Anne Church; Wu Lin; Lisbeth Illum; Audino Podda; Rino Rappuoli; Mariagrazia Pizza; George E Griffin; David J M Lewis
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

4.  Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance.

Authors:  H Bakke; K Lie; I L Haugen; G E Korsvold; E A Høiby; L M Naess; J Holst; I S Aaberge; F Oftung; B Haneberg
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

5.  Cellular Immune Responses in Humans Induced by Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines Given Separately and in Combination.

Authors:  Fredrik Oftung; Gro Ellen Korsvold; Audun Aase; Lisbeth M Næss
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

6.  Characterization of native outer membrane vesicles from lpxL mutant strains of Neisseria meningitidis for use in parenteral vaccination.

Authors:  Makda Fisseha; Ping Chen; Brenda Brandt; Todd Kijek; Elizabeth Moran; Wendell Zollinger
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

7.  Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection.

Authors:  B K Hvalbye; I S Aaberge; M Løvik; B Haneberg
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

8.  Immunogenicity of intranasally administered meningococcal native outer membrane vesicles in mice.

Authors:  N B Saunders; D R Shoemaker; B L Brandt; E E Moran; T Larsen; W D Zollinger
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

9.  Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity.

Authors:  Pamela T Wong; Su He Wang; Susan Ciotti; Paul E Makidon; Douglas M Smith; Yongyi Fan; Charles F Schuler; James R Baker
Journal:  Mol Pharm       Date:  2013-12-13       Impact factor: 4.939

10.  Influence of intravenous anesthesia on mucosal and systemic antibody responses to nasal vaccines.

Authors:  Libuse Janakova; Hilde Bakke; Inger Lise Haugen; Aud K H Berstad; E Arne Høiby; Ingeborg S Aaberge; Bjørn Haneberg
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.